These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22735122)

  • 1. [Lymphocytic hypophysitis due to ipilimumap therapy].
    Thomsen HH
    Ugeskr Laeger; 2012 Jun; 174(26):1829-30. PubMed ID: 22735122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ipilimumab-induced hypophysitis].
    Schleder S; Schreml S; Heiss P
    Rofo; 2013 Mar; 185(3):268-9. PubMed ID: 23154861
    [No Abstract]   [Full Text] [Related]  

  • 3. Hypophysitis: Nursing Management of Immune-Related Adverse Events
.
    Vazquez A
    Clin J Oncol Nurs; 2017 Apr; 21(2):154-156. PubMed ID: 28315541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab.
    van der Hiel B; Blank CU; Haanen JB; Stokkel MP
    Clin Nucl Med; 2013 Apr; 38(4):e182-4. PubMed ID: 23455528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipilimumab-induced hypophysitis: review of the literature.
    Araujo PB; Coelho MC; Arruda M; Gadelha MR; Neto LV
    J Endocrinol Invest; 2015 Nov; 38(11):1159-66. PubMed ID: 25957829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
    Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
    Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
    Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
    Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
    Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
    J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab for advanced melanoma: a nursing perspective.
    Ledezma B
    Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypophysitis caused by ipilimumab in cancer patients: hormone replacement or immunosuppressive therapy.
    Lammert A; Schneider HJ; Bergmann T; Benck U; Krämer BK; Gärtner R; Metzner C; Schöfl C; Berking C
    Exp Clin Endocrinol Diabetes; 2013 Nov; 121(10):581-7. PubMed ID: 24122241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyponatremia associated with Ipilimumab-induced hypophysitis.
    Barnard ZR; Walcott BP; Kahle KT; Nahed BV; Coumans JV
    Med Oncol; 2012 Mar; 29(1):374-7. PubMed ID: 21264545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient.
    Kaehler KC; Egberts F; Lorigan P; Hauschild A
    Melanoma Res; 2009 Oct; 19(5):333-4. PubMed ID: 19512947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
    Faje AT; Sullivan R; Lawrence D; Tritos NA; Fadden R; Klibanski A; Nachtigall L
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4078-85. PubMed ID: 25078147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
    Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
    Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipilimumab-induced hypophysitis: MR imaging findings.
    Carpenter KJ; Murtagh RD; Lilienfeld H; Weber J; Murtagh FR
    AJNR Am J Neuroradiol; 2009 Oct; 30(9):1751-3. PubMed ID: 19474123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
    Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
    Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.
    Hoos A; Ibrahim R; Korman A; Abdallah K; Berman D; Shahabi V; Chin K; Canetta R; Humphrey R
    Semin Oncol; 2010 Oct; 37(5):533-46. PubMed ID: 21074069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
    Boasberg P; Hamid O; O'Day S
    Semin Oncol; 2010 Oct; 37(5):440-9. PubMed ID: 21074058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma.
    Bernardo SG; Moskalenko M; Pan M; Shah S; Sidhu HK; Sicular S; Harcharik S; Chang R; Friedlander P; Saenger YM
    Melanoma Res; 2013 Feb; 23(1):47-54. PubMed ID: 23262440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.
    Johnson DB; Friedman DL; Berry E; Decker I; Ye F; Zhao S; Morgans AK; Puzanov I; Sosman JA; Lovly CM
    Cancer Immunol Res; 2015 May; 3(5):464-9. PubMed ID: 25649350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.